Excede (ceftiofur crystalline free acid) Sterile Suspension from Pfizer Animal Health is now approved by the U.S. Center for Veterinary Medicine and the Food and Drug Administration for the control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis in groups of pigs where SRD has been diagnosed.
“This new claim is another milestone in our commitment to veterinarians to provide tools to better control disease,” says Michael Senn, DVM, MS, manager, veterinary operations for Pfizer Animal Health. “Many pork operations fight SRD pathogens on an ongoing basis. Excede has provided successful treatment to sick pigs and now can be used to control disease in herds with an SRD diagnosis.”
Excede has been clinically proven to deliver at least seven days of therapeutic plasma levels with a single dose. “This means it starts working right away and continues to provide therapy for an extended period,” says Senn.
Excede is also indicated for the treatment of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis. The product requires a low-volume dose and is available in 100 mL size.
For more information about the proper use of Excede in pork operations, producers should talk with their veterinarian or local Pfizer Animal Health representative. Excede for Swine should not be administered to pigs known to be hypersensitive to cephalosporins or penicillins. Following label use as a single treatment, a 14-day pre-slaughter withdrawal period is required.